Jennewein Biotechnologie GmbH, a science-based company for developing and producing human milk oligosaccharides (HMOs) and rare monosaccharides, announced that it has established its subsidiary in the USA. Jennewein Biotech USA Corporation, a Delaware Corporation, using warehouses in Chicago, and Columbus, Ohio, will help to better serve our US and North American customers.
"The US market was always particularly important to us and usually is the market where new innovations hit first. The US market was the market where we launched 2'FL first in 2015, and will be also the first for launching our newest innovation, a 5 HMO blend" adds Stefan
Jennewein, CEO of Jennewein Biotechnologie. "The opening of our new subsidiary will strengthen our bond with our US domestic customers" says Glyn Brookman, Director of worldwide sales at Jennewein Biotechnologie.
